Document Detail


Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.
MedLine Citation:
PMID:  3516395     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients with acute myelogenous leukemia in relapse who were ineligible for further anthracycline therapy either because they were judged to be anthracycline resistant or had received the maximum doses were randomized to receive high-dose cytarabine (3 g/m2 every 12 hours for 6 days) or amsacrine (75 mg/m2 daily for 7 days). The response rates in both groups were similar: three of 25 patients given high-dose cytarabine and three of 23 given amsacrine obtained complete remissions.
Authors:
W R Vogler; H D Preisler; E F Winton; A J Gottlieb; J Goldberg; J Brennan; H Grunwald; K Rai; G Browman; K B Miller
Related Documents :
2028785 - High-dose intravenous gammaglobulin for neonatal alloimmune thrombocytopenia in twins.
3886255 - Kinetics of methylprednisolone and its hemisuccinate ester.
6945865 - The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelog...
997595 - Neutropenia during high dose intravenous oxacillin therapy.
10856535 - Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholest...
1171645 - Control of estrus with prostaglandin f2alpha in mares: minimal effective dose and stage...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Cancer treatment reports     Volume:  70     ISSN:  0361-5960     ISO Abbreviation:  Cancer Treat Rep     Publication Date:  1986 Apr 
Date Detail:
Created Date:  1986-06-19     Completed Date:  1986-06-19     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7607107     Medline TA:  Cancer Treat Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  455-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aminoacridines / adverse effects,  therapeutic use*
Amsacrine
Antibiotics, Antineoplastic / therapeutic use
Bone Marrow / pathology
Clinical Trials as Topic
Cytarabine / administration & dosage*,  adverse effects
Drug Resistance
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*,  pathology
Male
Middle Aged
Naphthacenes / therapeutic use
Random Allocation
Chemical
Reg. No./Substance:
0/Aminoacridines; 0/Antibiotics, Antineoplastic; 0/Naphthacenes; 147-94-4/Cytarabine; 51264-14-3/Amsacrine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High-dose melphalan with or without marrow transplantation: a study of dose-effect in patients with ...
Next Document:  Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric ...